Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Replimune Group (NASDAQ: REPL), a clinical stage biotechnology company focused on oncolytic immunotherapies, has granted inducement equity awards to 18 new non-executive employees. The awards include:
- Non-qualified stock options to purchase 21,960 shares with an exercise price of $10.01 per share - Restricted stock units representing 44,005 shares
The stock options have a 10-year term with 25% vesting after one year and the remainder vesting monthly over three years. The RSUs will vest in four annual installments starting May 15, 2026. These awards were granted under the company's 2025 Inducement Plan and approved by the compensation committee under Nasdaq Rule 5635(c)(4).
Replimune Group (NASDAQ: REPL), un'azienda biotecnologica in fase clinica specializzata in immunoterapie oncolitiche, ha concesso premi azionari di incentivo a 18 nuovi dipendenti non esecutivi. I premi includono:
- Opzioni su azioni non qualificate per l'acquisto di 21.960 azioni con un prezzo di esercizio di 10,01 $ per azione
- Unità di azioni vincolate (RSU) rappresentanti 44.005 azioni
Le opzioni hanno una durata di 10 anni, con il 25% che matura dopo un anno e il resto che matura mensilmente nei successivi tre anni. Le RSU matureranno in quattro rate annuali a partire dal 15 maggio 2026. Questi premi sono stati concessi nell'ambito del Piano di Incentivazione 2025 della società e approvati dal comitato per la remunerazione secondo la Regola Nasdaq 5635(c)(4).
Replimune Group (NASDAQ: REPL), una empresa biotecnológica en fase clínica centrada en inmunoterapias oncolíticas, ha otorgado premios de acciones inducidas a 18 nuevos empleados no ejecutivos. Los premios incluyen:
- Opciones sobre acciones no calificadas para comprar 21,960 acciones con un precio de ejercicio de $10.01 por acción
- Unidades de acciones restringidas (RSU) que representan 44,005 acciones
Las opciones tienen un plazo de 10 años, con un 25% que se consolida después de un año y el resto que se consolida mensualmente durante los siguientes tres años. Las RSU se consolidarán en cuatro cuotas anuales a partir del 15 de mayo de 2026. Estos premios fueron otorgados bajo el Plan de Inducción 2025 de la compañía y aprobados por el comité de compensación conforme a la Regla Nasdaq 5635(c)(4).
Replimune Group (NASDAQ: REPL)는 온콜리틱 면역치료에 중점을 둔 임상 단계의 바이오테크 기업으로, 18명의 신규 비임원 직원에게 유인 주식 보상을 부여했습니다. 보상 내용은 다음과 같습니다:
- 주당 $10.01의 행사가격으로 21,960주의 비자격 주식매수선택권
- 44,005주의 제한 주식 단위(RSU)
주식매수선택권은 10년의 유효기간을 가지며, 1년 후 25%가 베스팅되고 나머지는 3년 동안 매월 베스팅됩니다. RSU는 2026년 5월 15일부터 4년에 걸쳐 연간 분할 베스팅됩니다. 이 보상은 회사의 2025년 유인 계획에 따라 부여되었으며, Nasdaq 규칙 5635(c)(4)에 따라 보상위원회의 승인을 받았습니다.
Replimune Group (NASDAQ : REPL), une société biotechnologique en phase clinique spécialisée dans les immunothérapies oncolytiques, a accordé des attributions d'actions d'incitation à 18 nouveaux employés non cadres. Ces attributions comprennent :
- Des options d'achat d'actions non qualifiées pour acquérir 21 960 actions au prix d'exercice de 10,01 $ par action
- Des unités d'actions restreintes (RSU) représentant 44 005 actions
Les options ont une durée de 10 ans, avec 25 % qui deviennent acquises après un an, le reste s'acquérant mensuellement sur trois ans. Les RSU seront acquises en quatre versements annuels à partir du 15 mai 2026. Ces attributions ont été accordées dans le cadre du Plan d'Incitation 2025 de la société et approuvées par le comité de rémunération conformément à la règle Nasdaq 5635(c)(4).
Replimune Group (NASDAQ: REPL), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf onkolytische Immuntherapien, hat Anreizaktienzuteilungen an 18 neue nicht geschäftsführende Mitarbeiter vergeben. Die Zuteilungen umfassen:
- Nicht qualifizierte Aktienoptionen zum Kauf von 21.960 Aktien zu einem Ausübungspreis von 10,01 $ pro Aktie
- Restricted Stock Units (RSUs) in Höhe von 44.005 Aktien
Die Aktienoptionen haben eine Laufzeit von 10 Jahren, wobei 25 % nach einem Jahr unverfallbar werden und der Rest monatlich über drei Jahre vestet. Die RSUs werden in vier jährlichen Raten ab dem 15. Mai 2026 vesten. Diese Zuteilungen wurden im Rahmen des Inducement Plans 2025 des Unternehmens gewährt und vom Vergütungsausschuss gemäß Nasdaq-Regel 5635(c)(4) genehmigt.
- None.
- None.
WOBURN, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
The Company granted equity awards to 18 employees as a material inducement to commencing their employment with the Company under the Company’s 2025 Inducement Grant Incentive Compensation Plan (the “Inducement Plan”). The inducement awards consist of non-qualified stock options to purchase an aggregate of 21,960 shares of the Company's common stock and restricted stock units representing an aggregate of 44,005 shares of the Company's common stock. Each option has an exercise price of
The aforementioned inducement awards were approved by the compensation committee of the Company's board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). The inducement awards are subject to the terms and conditions set forth under the Inducement Plan.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
Investor Inquiries
Chris Brinzey
ICR Westwicke
339.970.2843
chris.brinzey@westwicke.com
Media Inquiries
Arleen Goldenberg
Replimune
917.548.1582
media@replimune.com
FAQ
What equity awards did Replimune (REPL) grant to new employees in May 2025?
What is the vesting schedule for REPL's May 2025 inducement stock options?
When do Replimune's May 2025 inducement RSUs begin vesting?
Under what Nasdaq rule were Replimune's May 2025 inducement grants approved?
